Vaxcyte, Inc. Research And Development Expense

Quick Answer

Vaxcyte, Inc. reported Research And Development Expense of $794.31 million for the year ending 2025.

  • Vaxcyte, Inc. showed an increase of +66.6% in Research And Development Expense from 2024 to 2025.
  • This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Vaxcyte, Inc.'s Research And Development Expense has grown by 2,535.0%.
  • Historical annual values: Fiscal year 2025: $794.31 million | Fiscal year 2024: $476.64 million | Fiscal year 2023: $332.34 million | Fiscal year 2022: $169.45 million | Fiscal year 2021: $78.41 million | Fiscal year 2020: $73.56 million | Fiscal year 2019: $45.61 million | Fiscal year 2018: $30.15 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: